Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection

Shanshan He, Billy Lin, Virginia Chu, Zongyi Hu, Xin Hu, Jingbo Xiao, Amy Q. Wang, Cameron J. Schweitzer, Qisheng Li, Michio Imamura, Nobuhiko Hiraga, Noel Southall, Marc Ferrer, Wei Zheng, Kazuaki Chayama, Juan J. Marugan, T. Jake Liang

Research output: Contribution to journalArticle

Abstract

Hepatitis C virus (HCV) infection affects an estimated 185million peopleworldwide,with chronic infection often leading to liver cirrhosis and hepatocellular carcinoma. Although HCV is curable, there is an unmet need for the development of effective and affordable treatment options. Through a cell-based high-throughput screen,we identified chlorcyclizine HCl (CCZ), an over-the-counter drug for allergy symptoms, as a potent inhibitor of HCV infection. CCZ inhibited HCV infection in human hepatoma cells and primary human hepatocytes. Themode of action of CCZ is mediated by inhibiting an early stage ofHCV infection, probably targeting viral entry into host cells. The in vitro antiviral effect of CCZ was synergistic with other anti-HCV drugs, including ribavirin, interferon-a, telaprevir, boceprevir, sofosbuvir, daclatasvir, and cyclosporin A, without significant cytotoxicity, suggesting its potential in combination therapy of hepatitis C. In the mouse pharmacokinetic model, CCZ showed preferential liver distribution. In chimeric mice engrafted with primary human hepatocytes, CCZ significantly inhibited infection of HCV genotypes 1b and 2a, without evidence of emergence of drug resistance, during 4 and 6 weeks of treatment, respectively. With its established clinical safety profile as an allergy medication, affordability, and a simple chemical structure for optimization, CCZ represents a promising candidate for drug repurposing and further development as an effective and accessible agent for treatment of HCV infection.

Original languageEnglish (US)
Article number282ra49
JournalScience Translational Medicine
Volume7
Issue number282
DOIs
StatePublished - Apr 8 2015
Externally publishedYes

Fingerprint

Histamine Antagonists
Virus Diseases
Hepacivirus
Hepatocytes
Hepatocellular Carcinoma
Drug Repositioning
Infection
Nonprescription Drugs
Drug Hypersensitivity
Ribavirin
Hepatitis C
chlorcyclizine
Drug Resistance
Liver Cirrhosis
Interferons
Cyclosporine
Antiviral Agents
Hypersensitivity
Pharmacokinetics
Genotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. / He, Shanshan; Lin, Billy; Chu, Virginia; Hu, Zongyi; Hu, Xin; Xiao, Jingbo; Wang, Amy Q.; Schweitzer, Cameron J.; Li, Qisheng; Imamura, Michio; Hiraga, Nobuhiko; Southall, Noel; Ferrer, Marc; Zheng, Wei; Chayama, Kazuaki; Marugan, Juan J.; Liang, T. Jake.

In: Science Translational Medicine, Vol. 7, No. 282, 282ra49, 08.04.2015.

Research output: Contribution to journalArticle

He, S, Lin, B, Chu, V, Hu, Z, Hu, X, Xiao, J, Wang, AQ, Schweitzer, CJ, Li, Q, Imamura, M, Hiraga, N, Southall, N, Ferrer, M, Zheng, W, Chayama, K, Marugan, JJ & Liang, TJ 2015, 'Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection', Science Translational Medicine, vol. 7, no. 282, 282ra49. https://doi.org/10.1126/scitranslmed.3010286
He, Shanshan ; Lin, Billy ; Chu, Virginia ; Hu, Zongyi ; Hu, Xin ; Xiao, Jingbo ; Wang, Amy Q. ; Schweitzer, Cameron J. ; Li, Qisheng ; Imamura, Michio ; Hiraga, Nobuhiko ; Southall, Noel ; Ferrer, Marc ; Zheng, Wei ; Chayama, Kazuaki ; Marugan, Juan J. ; Liang, T. Jake. / Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. In: Science Translational Medicine. 2015 ; Vol. 7, No. 282.
@article{23234c4ab97d42cfa3673aacfc767fdb,
title = "Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection",
abstract = "Hepatitis C virus (HCV) infection affects an estimated 185million peopleworldwide,with chronic infection often leading to liver cirrhosis and hepatocellular carcinoma. Although HCV is curable, there is an unmet need for the development of effective and affordable treatment options. Through a cell-based high-throughput screen,we identified chlorcyclizine HCl (CCZ), an over-the-counter drug for allergy symptoms, as a potent inhibitor of HCV infection. CCZ inhibited HCV infection in human hepatoma cells and primary human hepatocytes. Themode of action of CCZ is mediated by inhibiting an early stage ofHCV infection, probably targeting viral entry into host cells. The in vitro antiviral effect of CCZ was synergistic with other anti-HCV drugs, including ribavirin, interferon-a, telaprevir, boceprevir, sofosbuvir, daclatasvir, and cyclosporin A, without significant cytotoxicity, suggesting its potential in combination therapy of hepatitis C. In the mouse pharmacokinetic model, CCZ showed preferential liver distribution. In chimeric mice engrafted with primary human hepatocytes, CCZ significantly inhibited infection of HCV genotypes 1b and 2a, without evidence of emergence of drug resistance, during 4 and 6 weeks of treatment, respectively. With its established clinical safety profile as an allergy medication, affordability, and a simple chemical structure for optimization, CCZ represents a promising candidate for drug repurposing and further development as an effective and accessible agent for treatment of HCV infection.",
author = "Shanshan He and Billy Lin and Virginia Chu and Zongyi Hu and Xin Hu and Jingbo Xiao and Wang, {Amy Q.} and Schweitzer, {Cameron J.} and Qisheng Li and Michio Imamura and Nobuhiko Hiraga and Noel Southall and Marc Ferrer and Wei Zheng and Kazuaki Chayama and Marugan, {Juan J.} and Liang, {T. Jake}",
year = "2015",
month = "4",
day = "8",
doi = "10.1126/scitranslmed.3010286",
language = "English (US)",
volume = "7",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "282",

}

TY - JOUR

T1 - Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection

AU - He, Shanshan

AU - Lin, Billy

AU - Chu, Virginia

AU - Hu, Zongyi

AU - Hu, Xin

AU - Xiao, Jingbo

AU - Wang, Amy Q.

AU - Schweitzer, Cameron J.

AU - Li, Qisheng

AU - Imamura, Michio

AU - Hiraga, Nobuhiko

AU - Southall, Noel

AU - Ferrer, Marc

AU - Zheng, Wei

AU - Chayama, Kazuaki

AU - Marugan, Juan J.

AU - Liang, T. Jake

PY - 2015/4/8

Y1 - 2015/4/8

N2 - Hepatitis C virus (HCV) infection affects an estimated 185million peopleworldwide,with chronic infection often leading to liver cirrhosis and hepatocellular carcinoma. Although HCV is curable, there is an unmet need for the development of effective and affordable treatment options. Through a cell-based high-throughput screen,we identified chlorcyclizine HCl (CCZ), an over-the-counter drug for allergy symptoms, as a potent inhibitor of HCV infection. CCZ inhibited HCV infection in human hepatoma cells and primary human hepatocytes. Themode of action of CCZ is mediated by inhibiting an early stage ofHCV infection, probably targeting viral entry into host cells. The in vitro antiviral effect of CCZ was synergistic with other anti-HCV drugs, including ribavirin, interferon-a, telaprevir, boceprevir, sofosbuvir, daclatasvir, and cyclosporin A, without significant cytotoxicity, suggesting its potential in combination therapy of hepatitis C. In the mouse pharmacokinetic model, CCZ showed preferential liver distribution. In chimeric mice engrafted with primary human hepatocytes, CCZ significantly inhibited infection of HCV genotypes 1b and 2a, without evidence of emergence of drug resistance, during 4 and 6 weeks of treatment, respectively. With its established clinical safety profile as an allergy medication, affordability, and a simple chemical structure for optimization, CCZ represents a promising candidate for drug repurposing and further development as an effective and accessible agent for treatment of HCV infection.

AB - Hepatitis C virus (HCV) infection affects an estimated 185million peopleworldwide,with chronic infection often leading to liver cirrhosis and hepatocellular carcinoma. Although HCV is curable, there is an unmet need for the development of effective and affordable treatment options. Through a cell-based high-throughput screen,we identified chlorcyclizine HCl (CCZ), an over-the-counter drug for allergy symptoms, as a potent inhibitor of HCV infection. CCZ inhibited HCV infection in human hepatoma cells and primary human hepatocytes. Themode of action of CCZ is mediated by inhibiting an early stage ofHCV infection, probably targeting viral entry into host cells. The in vitro antiviral effect of CCZ was synergistic with other anti-HCV drugs, including ribavirin, interferon-a, telaprevir, boceprevir, sofosbuvir, daclatasvir, and cyclosporin A, without significant cytotoxicity, suggesting its potential in combination therapy of hepatitis C. In the mouse pharmacokinetic model, CCZ showed preferential liver distribution. In chimeric mice engrafted with primary human hepatocytes, CCZ significantly inhibited infection of HCV genotypes 1b and 2a, without evidence of emergence of drug resistance, during 4 and 6 weeks of treatment, respectively. With its established clinical safety profile as an allergy medication, affordability, and a simple chemical structure for optimization, CCZ represents a promising candidate for drug repurposing and further development as an effective and accessible agent for treatment of HCV infection.

UR - http://www.scopus.com/inward/record.url?scp=84927644630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927644630&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3010286

DO - 10.1126/scitranslmed.3010286

M3 - Article

VL - 7

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 282

M1 - 282ra49

ER -